Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
News|Slideshows|September 14, 2024
Now Trending: Updated Colonoscopy Guidelines, Out-of-Pocket Caps for Cancer Patients
Author(s)Brian Nowosielski
Check out this recap of articles published on our sister sites during the past week.
Advertisement
Explore articles from the past week published on Drug Topics’ sister brands AJMC, Formulary Watch, and Managed Healthcare Executive. From trispecific antibodies to ChatGPT’s ability to outperform trainee doctors, read up on recent health care industry news.
READ MORE:
Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our
Advertisement
Related to this article
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nicotine Pouches Create Opportunity for Pharmacist Counseling
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Expert Discusses Flu and COVID-19 Vaccine Guidance
5